Skip To Main Content
Helgi H Helgason on Muck Rack

Helgi H Helgason

As seen in: JAMA Oncology, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Helgi H

Contact Helgi H, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Errors in Figures 2 and 3

|
By Karen Bolhuis, Helga Droogendijk, Helgi H Helgason, Mathijs P. Hendriks
| JAMA Oncology Verified
Errors in Figures 2 and 3 First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases Marinde J. G. Bond, MD; Karen Bolhuis, MD; Olaf J. L. Loosveld, MD; Jan Willem B. de Groot, MD; Helga Droogendijk, MD; Helgi H. Helgason, MD; Mathijs P. Hendriks, MD; Joost M. Klaase, MD; Geert Kazemier, MD; Mike S. L. Liem, MD; Arjen M. Rijken, MD; Cornelis Verhoef, MD; Johannes H.W. de Wilt, MD; Koert P. de Jong, MD; Michael F. Gerhards, MD; Martinus J.
Open in Who Shared Issue with article?

FOLFOX/FOLFIRI-Bevacizumab for Unresectable Colorectal Liver Metastases

|
By Jan Franko, Karen Bolhuis, Helga Droogendijk, Helgi H Helgason
| JAMA Oncology Verified
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases Marinde J. G. Bond, MD; Karen Bolhuis, MD; Olaf J. L. Loosveld, MD; Jan Willem B. de Groot, MD; Helga Droogendijk, MD; Helgi H. Helgason, MD; Mathijs P. Hendriks, MD; Joost M. Klaase, MD; Geert Kazemier, MD; Mike S. L. Liem, MD; Arjen M. Rijken, MD; Cornelis Verhoef, MD; Johannes H.W. de Wilt, MD; Koert P. de Jong, MD; Michael F.
Open in Who Shared Issue with article?

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

|
By Karen Bolhuis, Mathijs P. Hendriks, Helga Droogendijk, Helgi H Helgason
| The Lancet Verified
Background Patients with initially unresectable colorectal cancer liver metastases might qualify for local treatment with curative intent after reducing the tumour size by induction systemic treatment. We aimed to compare the currently most active induction regimens.
Open in Who Shared View Duplicates (38) Issue with article?
See all 3 articles